HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frédéric Simonin Selected Research

Analgesics (Analgesic Drugs)

10/2021Identification of an N-acylated-DArg-Leu-NH2 Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia.
6/2021Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.
11/2018Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia.
9/2018A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
1/2017Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide.
1/2017RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
12/2016Opioid-induced hyperalgesia: Cellular and molecular mechanisms.
1/2016Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.
7/2014Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities.
1/2014Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frédéric Simonin Research Topics

Disease

12Hyperalgesia
01/2022 - 01/2006
9Pain (Aches)
01/2022 - 03/2002
5Chronic Pain
01/2022 - 01/2006
2Respiratory Insufficiency (Respiratory Failure)
09/2018 - 01/2016
2Hypersensitivity (Allergy)
01/2017 - 12/2016
1Neoplasms (Cancer)
01/2021
1Obesity
06/2017
1Neuralgia (Stump Neuralgia)
01/2016
1Sleep Wake Disorders
01/2014

Drug/Important Bio-Agent (IBA)

13Opioid Analgesics (Opioids)IBA
01/2022 - 01/2006
10Analgesics (Analgesic Drugs)IBA
10/2021 - 01/2014
5Opiate AlkaloidsIBA
11/2018 - 01/2014
5phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamideIBA
11/2018 - 01/2006
5Morphine (MS Contin)FDA LinkGeneric
09/2018 - 12/2013
4Fentanyl (Sublimaze)FDA LinkGeneric
10/2021 - 01/2017
4neuropeptide FF receptorIBA
11/2018 - 01/2006
4AmidesIBA
01/2017 - 12/2013
4Peptides (Polypeptides)IBA
04/2016 - 12/2013
2DipeptidesIBA
10/2021 - 11/2018
2LigandsIBA
11/2018 - 01/2016
1NeuropeptidesIBA
10/2021
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
10/2021
1Pharmaceutical PreparationsIBA
01/2021
1HydrazonesIBA
11/2018
1pimagedine (aminoguanidine)IBA
11/2018
1Oxycodone (Oxycontin)FDA LinkGeneric
09/2018
1Hormones (Hormone)IBA
06/2017
1morphine-3-glucuronideIBA
01/2017
1mu Opioid Receptors (mu Opioid Receptor)IBA
01/2017
1NociceptinIBA
01/2016
1OrnithineIBA
03/2015
1PeptidomimeticsIBA
03/2015
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2014
1MT1 Melatonin ReceptorIBA
01/2014
1Heroin (Diamorphine)IBA
01/2006
1Opioid Peptides (Opioid Peptide)IBA
03/2002

Therapy/Procedure

5Analgesia
01/2022 - 12/2013